Postmarketing safety reports for the collagenase-based product Xiaflex [Xiapex] show no unexpected findings,

Excerpt

Postmarketing safety reports for the collagenase-based product Xiaflex [Xiapex] show no unexpected findings, according to developer BioSpecifics Technologies Corp. and strategic partner Auxilium Pharmaceuticals. Adverse events reports received during the first 30 months after approval of Xiaflex in the US for the treatment of Dupuytren's contracture in adults showed no clinically meaningful differences in its tolerability profile compared with clinical trials. Between 2 February 2010 and 31 July 2012, 1454 adverse events were reported among the approximately 21 000 patients in the US who received a total of approximately 27 000 injections of Xiaflex. The most common events were laceration, peripheral edema and bruising. …